| | “The Trends Behind Successful Cancer Treatments” Powerful new cancer treatments such as CAR T-cell therapy, anti-cancer vaccines and immunotherapies are showing unprecedented response rates and bringing patients new hope. The uptick of successes are generating optimism among scientists and companies looking to get their drug to market. Is your approach setting you up for success? Unlock More Potential with TD2. |
Today's Rundown Lilly bags late-phase Dupixent rival in $1.1B Dermira buyout Aduro's staffers feel the sting, again, after Novartis walks away Blackstone lands $3.4B life science fund, plots more fundraising Ultragenyx shares jump on 'better than expected' gene therapy data Roche taps Amunix's tech in $40M non-cancer R&D deal Tyra Biosciences takes aim at treatment-resistant tumors with $50M raise Generation Bio grabs a $110M round to ramp up work on next-gen gene therapies How controlling fat 'doormen' could lead to new obesity treatments EuroBiotech Report—NorthSea B round, Boehringer deal, AstraZeneca-MiNA, Galecto and Novo FiercePharmaAsia—Taiho, Otsuka, Chugai KRAS deals; Biocon biologics spinoff; Mark Alles' new title Chutes & Ladders—Pfizer's Read picks up position at asset manager Featured Story | | | Friday, January 10, 2020 Eli Lilly has struck a $1.1 billion deal to acquire Dermira, landing it a late-phase rival to Regeneron and Sanofi’s blockbuster atopic dermatitis drug Dupixent. The takeover, which values Dermira at just a whisker above its closing price yesterday, comes months after the biotech posted phase 2b data. |
|
|---|
|
| Thank you to Rho for sponsoring this year's JPM 2020 coverage. |
Top Stories Friday, January 10, 2020 It’s grim news ahead of the J.P. Morgan Healthcare Conference next week for Aduro Biotech. Friday, January 10, 2020 Blackstone has raised $3.4 billion for its life science fund. The financing, which could grow by another $1.2 billion, sets Blackstone up to continue placing bets such as its ventures with Novartis and Ferring. Friday, January 10, 2020 Ultragenyx Pharmaceutical saw its shares jump around 27% in trading Friday after announcing positive top-line data out of its gene therapy trial. Friday, January 10, 2020 As Amunix zeroes in on developing its own pipeline of cancer drugs, the company is licensing its platform, which lengthens the half-life of drugs, to Roche for $40 million upfront. The Swiss pharma will use it to discover and develop new drugs outside the realm of cancer. Friday, January 10, 2020 Tyra Biosciences is taking aim at treatment-resistant tumors, banking $50 million in its series A round to get on its way. The Carlsbad, California-based biotech will develop a pipeline of “very specific” small molecules to attack cancer cells that have rewired themselves to become resistant to targeted treatments. Friday, January 10, 2020 In 2018, Generation Bio broke cover with a $25 million series A, swiftly followed by a meatier $100 million second funding round. Friday, January 10, 2020 Fat cells take in nutrients and let out energy-supplying lipids in a finely tuned process that prevents the excessive buildup of belly fat. Scientists at Yale University have discovered that the enzyme O-GlcNAc transferase helps regulate this process. In mice, depleting the enzyme caused cells to burn off lipids at a faster rate than they took in carbohydrates. Thursday, January 9, 2020 In this week's EuroBiotech Report, NorthSea raises cash for NASH trial, Boehringer buys fibrosis assets and AstraZeneca forms metabolic disease pact. Friday, January 10, 2020 A group of Japanese drugmakers have found licensees for their KRAS-focused projects. Biocon secured a private equity investment for its biologics business in preparation for an IPO. Ex-Celgene chief Mark Alles re-emerged as a board director at Chinese biotech Antengene. And more. Friday, January 10, 2020 Pfizer ex-CEO Read picks up job at The Carlyle Group; AMAG dumps CEO Heiden; ex-Lilly chief Conterno joins team at Fibrogen. | | Experts in our field; with 20+ years’ experience in Viral Vector & plasmid DNA (R&D, High Quality and GMP) manufacture for pre-clinical, clinical & commercial supply. Take a virtual tour of our facilities & find out more about our expansion project. |
Enrollment Showcase | | | Sponsored by: Drexel University Online Drexel University’s online graduate programs in biomedicine, clinical research, drug discovery, and molecular medicine were developed with working professionals in mind, providing you with the education, practical skills, and competitive edge you need to be successful in your career. Learn more. |
|
|---|
|
Resources Sponsored by: ICON Clinical Research Ltd The beginning of this digital transformation is well underway and is likely to accelerate. Read our white paper, “Digital Disruption in Biopharma: How Digital Transformation can reverse declining ROI on R&D,” to learn more. Sponsored by: snapIoT, Inc. Download this white paper and read the expert feedback that snapIoT has gathered from industry thought leaders on the evolution, evaluation, and use of telemedicine solutions in clinical trials. Sponsored by: EVERSANA How are your launch strategies can convert “innovation” into value for patients? Sponsored by: Eli Lilly and Company in partnership with Xcenda Download this complimentary paper that explores the practice of step therapy and its impact on key stakeholders in the US healthcare system. Sponsored by: Amazon Web Services From IoT to data management to high-performance computing and machine learning, leading life sciences organizations are using Amazon Web Services (AWS) to develop scalable, global, predictable, and secure solutions to modernize clinical trials while mitigating risks Sponsored by: Outer Edge Technology, LLC Why companies leverage the expertize of industry focused cloud service providers to design and build quality systems and facilitate the FDA Validation of Mission Critical Apps in the Cloud. Sponsored by: Colorcon Learn more: Best practices for defending supply chain security and compliance by efficiently managing product authentication. Sponsored by: Metabolon Small or emerging pharmaceutical and biotech companies pursuing novel molecules and targets have two important goals: achieve clinical success and attract new rounds of funding. While there’s never a guarantee of either, certain actions can influence the outcome in your favor. Sponsored by: Catalent Learn how recent innovations in demand-led supply and direct-to-patient distribution are converging to create a next-generation clinical supply chain that is flexible, lean and most importantly patient-centric. Sponsored by: Altran This whitepaper highlights the challenges of implementing the right digital twin strategy while providing key use cases in the manufacturing domain for which a digital twin is extremely useful and several examples of technology trends that will shape the future. Sponsored by: Catalent Pharma Solutions In this Q&A, four Catalent Biologics experts share how scale-up, regulatory expectations, demand forecasting and process validation all play a role in the success of a biologic when embarking upon the commercial manufacturing journey. Asia-Pacific Healthcare Compliance Certificate Program March 9-12, 2020 FierceBiotech Executive Breakfast at the J.P. Morgan Healthcare Conference 2020 January 14, 2020 | The Fairmont Hotel | San Francisco, CA 11th Annual SCOPE Summit: Summit for Clinical Ops Executives February 18-21, 2020 | Orlando, FL BIO International Convention June 8-11, 2020 | San Diego, CA Middle East Healthcare Compliance Certificate Program March 23-26, 2020 |
